Somatostatin in Living Donor Liver Transplantation

• Status: Not yet recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Aim of the study is to investigate the safety and the efficacy of somatostatin as liver inflow modulator in patients with end-stage liver disease (ESLD) and clinically significant portal hypertension (CSPH) undergoing Adult-to-Adult living donor liver transplantation (A2ALDLT).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Faisal Specialist Hospital & Research Center
• Collaborators: CEINGE - Biotecnologie Avanzate, Napoli, Italia; Federico II University of Naples, Department of Clinical Medicine and Surgery, Naples, Italy
• Treatments: Somatostatin

Criteria

Inclusion Criteria:

• Adult patients (> 18 years old) undergoing Adult-to-Adult Living donor Liver Transplantation (LDLT) (right or left lobe)

• Indication for LDLT: End Stage Liver Disease with Portal Hypertension (HVPG ≥ 10mmHg)

Exclusion Criteria:

• Complete portal vein thrombosis (pre-operative or intraoperative diagnosis)

• Hepatopulmonary hypertension

• Adult-to-Adult Living donor liver transplantation for Fulminant hepatic failure

• Recipients of multiple solid organ transplants

• History of cardiac arrhythmias